Our findings provide important evidence for its oncogenic role in the breast tumor microenvironment, which suggests that targeting Wnt5a in the breast TME may provide a potential option for antiangiogenesis therapy in breast cancer. The gene discussed is WNT5A; the disease is breast carcinoma.